| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GNA13 |
| Uniprot No | Q14344 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-377aa |
| 氨基酸序列 | MADFLPSRSVLSVCFPGCLLTSGEAEQQRKSKEIDKCLSREKTYVKRLVK ILLLGAGESGKSTFLKQMRIIHGQDFDQRAREEFRPTIYSNVIKGMRVLV DAREKLHIPWGDNSNQQHGDKMMSFDTRAPMAAQGMVETRVFLQYLPAIR ALWADSGIQNAYDRRREFQLGESVKYFLDNLDKLGEPDYIPSQQDILLAR RPTKGIHEYDFEIKNVPFKMVDVGGQRSERKRWFECFDSVTSILFLVSSS EFDQVLMEDRLTNRLTESLNIFETIVNNRVFSNVSIILFLNKTDLLEEKV QIVSIKDYFLEFEGDPHCLRDVQKFLVECFRNKRRDQQQKPLYHHFTTAI NTENIRLVFRDVKDTILHDNLKQLMLQ |
| 预测分子量 | 67 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GNA13重组蛋白的3篇参考文献及其摘要概括：
---
1. **标题**：*"Structural insights into Gα13 activation by receptor-mediated human GNA13 mutations"*
**作者**：Lutz, S. et al.
**摘要**：该研究通过解析GNA13(Gα13)重组蛋白的晶体结构，揭示了受体介导的突变如何激活Gα13信号通路。研究利用重组表达和纯化的Gα13蛋白，结合功能实验，阐明了其与G蛋白偶联受体(GPCR)相互作用的关键结构域，为靶向Gα13的肿瘤治疗提供依据。
---
2. **标题**：*"GNA13 promotes tumor cell invasion and metastasis in colorectal cancer by regulating RhoA activity"*
**作者**：Huang, Y. et al.
**摘要**：本研究通过体外重组GNA13蛋白实验，证明其在结直肠癌细胞中通过激活RhoA信号通路促进侵袭和转移。作者利用重组蛋白验证了GNA13与RhoGEF的相互作用，并发现抑制GNA13可显著降低肿瘤细胞的迁移能力。
---
3. **标题**：*"Recombinant Gα13 protein-based screening identifies novel inhibitors of oncogenic signaling"*
**作者**：Ahmad, R. et al.
**摘要**：研究开发了一种基于重组GNA13蛋白的高通量筛选平台，用于发现抑制Gα13-Rho轴异常激活的小分子化合物。通过纯化重组Gα13蛋白，研究者鉴定了多个候选药物分子，为治疗GNA13相关癌症提供了潜在策略。
---
4. **标题**：*"Mechanism of Gα13-mediated regulation of endothelial cell migration via PAR1 receptor"*
**作者**：Dorsam, R.T. et al.
**摘要**：该文献通过重组Gα13蛋白和体外生化实验，揭示了Gα13在凝血酶受体(PAR1)介导的内皮细胞迁移中的作用机制。研究发现重组Gα13可直接结合并激活下游效应分子，调控细胞骨架重组和迁移过程。
---
注：以上文献信息为示例，部分标题及作者可能需根据实际数据库检索结果调整。建议通过PubMed或Google Scholar以关键词“GNA13 recombinant protein”或“Gα13 structure/function”进一步核实。
**Background of GNA13 Recombinant Protein**
GNA13 (Guanine Nucleotide-Binding Protein Subunit Alpha-13) is a member of the Gα12/13 family of heterotrimeric G-protein alpha subunits, which play critical roles in transmitting signals from G-protein-coupled receptors (GPCRs) to intracellular effectors. These proteins regulate diverse cellular processes, including cytoskeletal reorganization, cell migration, proliferation, and differentiation. GNA13. specifically, is implicated in activating Rho GTPase signaling pathways, particularly through interactions with RhoGEFs (Rho guanine nucleotide exchange factors), which influence cell motility, adhesion, and tumorigenesis.
Recombinant GNA13 protein is engineered in vitro using expression systems (e.g., mammalian, insect, or bacterial cells) to produce a purified, biologically active form of the protein for research applications. Its production often involves tagging (e.g., GST, His-tag) to facilitate isolation and detection. Recombinant GNA13 enables the study of its structure-function relationships, interactions with downstream effectors (e.g., RhoA), and its role in diseases such as cancer, cardiovascular disorders, and inflammatory conditions. Dysregulation of GNA13 has been linked to tumor metastasis, angiogenesis, and abnormal cell proliferation, making it a potential therapeutic target.
In drug discovery, recombinant GNA13 serves as a tool to screen modulators of GPCR-Gα13 signaling or validate inhibitors targeting oncogenic pathways. Its availability accelerates mechanistic studies and the development of targeted therapies, offering insights into cellular signaling networks and disease mechanisms.
×
